Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053209 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
A Phase 2 study of Bladder Cancer and Urethral Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT00053209 is a Phase 2 study of Bladder Cancer and Urethral Cancer that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 46 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00053209, a Phase 2 study of Bladder Cancer and Urethral Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining pemetrexed disodium with gemcitabine may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining pemetrexed disodium with gemcitabine in treating patients who have advanced cancer of the urothelium.
Conditions Studied
Interventions
- DRUG gemcitabine hydrochloride
- DRUG pemetrexed disodium
Study Locations (20)
Colorado
- Aurora Presbyterian Hospital - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
- Porter Adventist Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- St. Joseph Hospital - Denver
- Rose Medical Center - Denver
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
- Swedish Medical Center - Englewood
- Sky Ridge Medical Center - Lone Tree
- Hope Cancer Care Center at Longmont United Hospital - Longmont
- St. Mary-Corwin Regional Medical Center - Pueblo
- North Suburban Medical Center - Thornton
Delaware
- Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
- St. Francis Hospital - Wilmington
Florida
- Baptist Cancer Institute - Jacksonville - Jacksonville
- Watson Clinic, LLC - Lakeland
Connecticut
- Yale Comprehensive Cancer Center at Yale University School of Medicine - New Haven
Georgia
- Hematology and Oncology of Northeast Georgia - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2004-08-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053209
The ClinicalTrials.gov registry entry for NCT00053209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00053209 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Delaware, Florida.
Frequently Asked Questions
What is clinical trial NCT00053209 about?
NCT00053209 is a clinical study titled "Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium". RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining pemetrexed disodium with gemcitabine ...
What is the current status of trial NCT00053209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2004-08-10. Estimated completion is 2009-05.
What conditions does trial NCT00053209 study?
This clinical trial studies the following conditions: Bladder Cancer, Urethral Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter.
What interventions are being tested in trial NCT00053209?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT00053209?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00053209 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.